Ikaros-Notch axis in host hematopoietic cells regulates experimental graft-versus-host disease by Tomomi Toubai, Yaping Sun, Isao Tawara, Ann Friedman,

Slides:



Advertisements
Similar presentations
A Crucial Role for Host APCs in the Induction of Donor CD4 + CD25 + Regulatory T Cell-Mediated Suppression of Experimental Graft-versus-Host Disease Isao.
Advertisements

Recombinant CD95-Fc (APG101) prevents graft-versus-host disease in mice without disabling antitumor cytotoxicity and T-cell functions by Natalie Hartmann,
Joseph H. Chewning, Weiwei Zhang, David A. Randolph, C
Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease by Tangsheng Yi, Ying Chen, Lin Wang,
Cheng-Ming Sun, Edith Deriaud, Claude Leclerc, Richard Lo-Man  Immunity 
Host-Derived CD8+ Dendritic Cells Protect Against Acute Graft-versus-Host Disease after Experimental Allogeneic Bone Marrow Transplantation  Michael Weber,
Secondary Lymphoid Organs Contribute to, but Are Not Required for the Induction of Graft-versus-Host Responses following Allogeneic Bone Marrow Transplantation:
Influence of Donor Microbiota on the Severity of Experimental Graft-versus-Host- Disease  Isao Tawara, Chen Liu, Hiroya Tamaki, Tomomi Toubai, Yaping Sun,
Host-Derived Interleukin-18 Differentially Impacts Regulatory and Conventional T Cell Expansion During Acute Graft-Versus-Host Disease  Robert Zeiser,
Extracorporeal Photopheresis Attenuates Murine Graft-versus-Host Disease via Bone Marrow–Derived Interleukin-10 and Preserves Responses to Dendritic Cell.
IL-2–Targeted Therapy Ameliorates the Severity of Graft-versus-Host Disease: Ex Vivo Selective Depletion of Host-Reactive T Cells and In Vivo Therapy 
Juyang Kim, Wongyoung Kim, Hyun J. Kim, Sohye Park, Hyun-A
Differential Effects of Gut-Homing Molecules CC Chemokine Receptor 9 and Integrin-β7 during Acute Graft-versus-Host Disease of the Liver  Alina Schreder,
CCR2 is required for CD8-induced graft-versus-host disease
Notch signaling is a critical regulator of allogeneic CD4+ T-cell responses mediating graft-versus-host disease by Yi Zhang, Ashley R. Sandy, Jina Wang,
Induction of Immunity to Neuroblastoma Early after Syngeneic Hematopoietic Stem Cell Transplantation Using a Novel Mouse Tumor Vaccine  Weiqing Jing,
by Yoshinobu Maeda, Pavan Reddy, Kathleen P
by Dennis Adeegbe, Robert B. Levy, and Thomas R. Malek
Ping Zhang, Jieying Wu, Divino Deoliveira, Nelson J. Chao, Benny J
by Silke Huber, Reinhard Hoffmann, Femke Muskens, and David Voehringer
Induction of heme oxygenase-1 before conditioning results in improved survival and reduced graft-versus-host disease after experimental allogeneic bone.
by Norman Nausch, Ioanna E
Preventive Azithromycin Treatment Reduces Noninfectious Lung Injury and Acute Graft- versus-Host Disease in a Murine Model of Allogeneic Hematopoietic.
Macrophages from C3-deficient mice have impaired potency to stimulate alloreactive T cells by Wuding Zhou, Hetal Patel, Ke Li, Qi Peng, Marie-Bernadette.
Ex Vivo Rapamycin Generates Th1/Tc1 or Th2/Tc2 Effector T Cells With Enhanced In Vivo Function and Differential Sensitivity to Post-transplant Rapamycin.
IL-21 blockade reduces graft-versus-host disease mortality by supporting inducible T regulatory cell generation by Christoph Bucher, Lisa Koch, Christine.
B7-H3 expression in donor T cells and host cells negatively regulates acute graft-versus-host disease lethality by Rachelle G. Veenstra, Ryan Flynn, Katharina.
LBH589 Enhances T Cell Activation In Vivo and Accelerates Graft-versus-Host Disease in Mice  Dapeng Wang, Cristina Iclozan, Chen Liu, Changqing Xia, Claudio.
by Éric Aubin, Réal Lemieux, and Renée Bazin
The histone methyltransferase Ezh2 is a crucial epigenetic regulator of allogeneic T-cell responses mediating graft-versus-host disease by Shan He, Fang.
Simple conditioning with monospecific CD4+CD25+ regulatory T cells for bone marrow engraftment and tolerance to multiple gene products by David-Alexandre.
by Sheng F. Cai, Xuefang Cao, Anjum Hassan, Todd A
PreImplantation Factor Reduces Graft-versus-Host Disease by Regulating Immune Response and Lowering Oxidative Stress (Murine Model)  Yehudith Azar, Reut.
Blocking LFA-1 Activation with Lovastatin Prevents Graft-versus-Host Disease in Mouse Bone Marrow Transplantation  Yang Wang, Dan Li, Dan Jones, Roland.
IFNγ differentially controls the development of idiopathic pneumonia syndrome and GVHD of the gastrointestinal tract by Angela C. Burman, Tatjana Banovic,
IL-6 Blockade Attenuates the Development of Murine Sclerodermatous Chronic Graft- Versus-Host Disease  Doanh Le Huu, Takashi Matsushita, Guihua Jin, Yasuhito.
IL-17 Gene Ablation Does Not Impact Treg-Mediated Suppression of Graft-Versus-Host Disease after Bone Marrow Transplantation  Lucrezia Colonna, Mareike.
Pak2 regulates myeloid-derived suppressor cell development in mice
Evelyn C. Nieves, Tomomi Toubai, Daniel C
The Triterpenoid CDDO-Me Delays Murine Acute Graft-versus-Host Disease with the Preservation of Graft-versus-Tumor Effects after Allogeneic Bone Marrow.
Absence of donor Th17 leads to augmented Th1 differentiation and exacerbated acute graft-versus-host disease by Tangsheng Yi, Dongchang Zhao, Chia-Lei.
Volume 18, Issue 5, Pages (May 2003)
Inhibition of Cathepsin S Reduces Allogeneic T Cell Priming but Not Graft-versus-Host Disease Against Minor Histocompatibility Antigens  Hisaki Fujii,
Blocking Activator Protein 1 Activity in Donor Cells Reduces Severity of Acute Graft- Versus-Host Disease through Reciprocal Regulation of IL-17–Producing.
Essential Role of Interleukin-12/23p40 in the Development of Graft-versus-Host Disease in Mice  Yongxia Wu, David Bastian, Steven Schutt, Hung Nguyen,
T helper17 Cells Are Sufficient But Not Necessary to Induce Acute Graft-Versus-Host Disease  Cristina Iclozan, Yu Yu, Chen Liu, Yaming Liang, Tangsheng.
Volume 18, Issue 3, Pages (March 2003)
Host Basophils Are Dispensable for Induction of Donor T Helper 2 Cell Differentiation and Severity of Experimental Graft-versus-Host Disease  Isao Tawara,
Effector Cells Derived from Host CD8 Memory T Cells Mediate Rapid Resistance against Minor Histocompatibility Antigen-Mismatched Allogeneic Marrow Grafts.
A Radio-Resistant Perforin-Expressing Lymphoid Population Controls Allogeneic T Cell Engraftment, Activation, and Onset of Graft-versus-Host Disease in.
Dynamic Change and Impact of Myeloid-Derived Suppressor Cells in Allogeneic Bone Marrow Transplantation in Mice  Dapeng Wang, Yu Yu, Kelley Haarberg,
Mammalian Target of Rapamycin Inhibitors Permit Regulatory T Cell Reconstitution and Inhibit Experimental Chronic Graft-versus-Host Disease  Haruko Sugiyama,
Tracking ex vivo-expanded CD4+CD25+ and CD8+CD25+ regulatory T cells after infusion to prevent donor lymphocyte infusion-induced lethal acute graft-versus-host.
In Situ Activation and Expansion of Host Tregs: A New Approach to Enhance Donor Chimerism and Stable Engraftment in Major Histocompatibility Complex-Matched.
Volume 27, Issue 3, Pages (September 2007)
CD25 expression distinguishes functionally distinct alloreactive CD4+ CD134+ (OX40+) T-cell subsets in acute graft-versus-host disease  Philip R Streeter,
Volume 32, Issue 5, Pages (May 2010)
by Derek Hoi-Hang Ho, and Roger Hoi-Fung Wong
Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation  Jian-Ming Li, Edmund K.
Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD4+25+ T cells to allow an effective graft-versus-leukemia response 
Raimon Duran-Struuck, Isao Tawara, Kathi Lowler, Shawn G
Volume 16, Issue 1, Pages (July 2014)
IAPs protect host target tissues from graft-versus-host disease in mice by Tomomi Toubai, Corinne Rossi, Katherine Oravecz-Wilson, Chen Liu, Cynthia Zajac,
PD-1 blockade enhances T-cell function.
Roles of CD28, CTLA4, and Inducible Costimulator in Acute Graft-versus-Host Disease in Mice  Jun Li, Kenrick Semple, Woong-Kyung Suh, Chen Liu, Fangping.
Conventional dendritic cells are the critical donor APC presenting alloantigen after experimental bone marrow transplantation by Kate A. Markey, Tatjana.
Pretreatment of donor T cells with a c-Rel antagonist does not impair GVT activity. Pretreatment of donor T cells with a c-Rel antagonist does not impair.
Rapamycin inhibits IL-4—induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo by Holger Hackstein, Timucin Taner,
Volume 37, Issue 2, Pages (August 2012)
Volume 10, Issue 5, Pages (February 2015)
Presentation transcript:

Ikaros-Notch axis in host hematopoietic cells regulates experimental graft-versus-host disease by Tomomi Toubai, Yaping Sun, Isao Tawara, Ann Friedman, Chen Liu, Rebecca Evers, Evelyn Nieves, Chelsea Malter, Peter Chockley, Ivan Maillard, Susan Winandy, and Pavan Reddy Blood Volume 118(1):192-204 July 7, 2011 ©2011 by American Society of Hematology

Ikaros deficiency in host APCs exacerbates GVHD. (A) WT B6 Ly5 Ikaros deficiency in host APCs exacerbates GVHD. (A) WT B6 Ly5.2 animals were lethally irradiated with 11 Gy and infused with 5 × 106 BM cells and 5 × 106 splenocytes from syngeneic Ly5.1 WT B6 or Ik−/− B6 donors. Ikaros deficiency in host APCs exacerbates GVHD. (A) WT B6 Ly5.2 animals were lethally irradiated with 11 Gy and infused with 5 × 106 BM cells and 5 × 106 splenocytes from syngeneic Ly5.1 WT B6 or Ik−/− B6 donors. Four months later, these animals [B6 → B6Ly5.2] or [Ik−/− → B6Ly5.2] chimeras received 9 Gy and 2 × 106 CD90+ T cells along with 5 × 106 BM cells from either syngeneic B6 or allogeneic MHC-matched, multiple miHA-mismatched C3H.sw donors and analyzed for survival. Shown are B6 → [B6 → B6Ly5.2] (n = 7) (■), B6 → [Ik−/− → B6Ly5.2] (n = 6) (♦), C3H.sw → [B6 → B6 Ly5.2] (n = 12) (▴), and C3H.sw → [Ik−/− → B6Ly5.2] (n = 11) (●). ***P < .001 for C3H.sw → [B6 → B6Ly5.2] compared with C3H.sw → [Ik−/− → B6Ly5.2]. Data are representative of 2 independent experiments. (B) Representative hematoxylin and eosin–stained images and histopathologic score of gastrointestinal tracts (small and large bowels), liver, and skin on days +14 and +21 after allogeneic BMT. Each group includes 5-9 mice. (C) Serum IFN-γ and IL-17A levels at day 7. Each group includes 5-9 mice. (D) Donor T-effector and Treg expansion and ex vivo suppression. Donor CD8+ T-cell expansion was analyzed in splenocytes harvested on day +14 from allogeneic [B6 → Ly5.2] or [Ik−/− → B6Ly5.2] chimeras (n = 5 animals/group) as shown by the black bars versus the gray bars, respectively (P < .05). Donor CD4+CD25+Foxp3+ Treg expansion was analyzed in the spleens harvested on days +14 and +21 and in the liver harvested on day +21 from the allogeneic [B6 → Ly5.2] or [Ik−/− → B6Ly5.2] animals (n = 5 animals/group) as shown by the black bars versus the gray bars, respectively (P = not significant at both day +14 and day +21). The donor CD4+CD25+ and the CD4+CD25− T cells were isolated from the livers (pooled from 5 mice/group) harvested on day +21 from the allogeneic [B6 → Ly5.2] or [Ik−/− → B6Ly5.2] animals. The suppressive function of CD4+CD25+ T cells was analyzed by coculturing the isolated 2.5 × 103 CD4+CD25+ T cells with 104 CD4+CD25− T cells in the presence of 5 × 104 irradiated WT B6 spleen cells for 120 hours. Incorporation of 3H-thymidine (1 μCi/well) by proliferating cells was measured during the last 6 hours of culture. Data show means ± SEM. P = not significant. Data are from 1 of 2 similar experiments. (E) WT B6 Ly5.2 animals were lethally irradiated with 11 Gy and infused with 5 × 106 BM cells and 5 × 106 splenocytes from syngeneic Ly5.1 WT B6 or Ik−/− B6 donors. Four months later, [B6 → B6Ly5.2] or [Ik−/− → B6Ly5.2]) animals were irradiated with 9 Gy and transplanted with 2 × 106 CD90+ T cells along with 5 × 106 BM cells from either syngeneic B6 or allogeneic MHC-mismatched BALB/c donors and analyzed for survival. Shown are B6 → [B6 → B6Ly5.2] (n = 7) (■), BALB/c → [B6 → B6Ly5.2] (n = 10) (▴), and BALB/c → [Ik−/− → B6Ly5.2] (n = 13) (●) animals. Data are representative of 2 independent experiments. (F) WT B6Ly5.2 animals were lethally irradiated with 11 Gy and infused with 5 × 106 BM cells and 5 × 106 splenocytes from syngeneic Ly5.1 WT B6 or IkDN+/− B6 donors. Four months later, [B6 → B6Ly5.2] or [IkDN+/− → B6Ly5.2]) animals were used as recipients, irradiated with 9 Gy, and transplanted with 2 × 106 CD90+ T cells along with 5 × 106 BM cells from either syngeneic B6 or allogeneic MHC-matched, miHA-mismatched C3H.sw donors, and the animals were evaluated for survival. Shown are B6 → [B6 → B6Ly5.2] (n = 6) (■), C3H.sw → [B6 → B6 Ly5.2] (n = 9) (▴), and C3H.sw → [IkDN+/− → B6Ly5.2] (n = 11) ●. Data are representative of 2 independent experiments. Tomomi Toubai et al. Blood 2011;118:192-204 ©2011 by American Society of Hematology

Splenic DC phenotype in the absence of Ikaros. Splenic DC phenotype in the absence of Ikaros. The total splenocyte count and the frequency and the expression of costimulation molecules on CD11c+ cells were analyzed from naive Ik−/− and WT B6 animals that were not transplanted (n = 5-7/group). *P < .05; **P < .01; ***P < .001. (A) Total splenocyte count. (B) Expression of CD11c and CD8. The black and gray boxes signify CD8+CD11c+ DCs and CD8−CD11c+ DCs, respectively. (C) Frequency and absolute number of CD11c+ DCs. (D) Frequency and absolute number of CD8+CD11c+ DCs and CD8−CD11c+ DCs in spleen. The expression of the costimulatory molecules CD80 (E), CD86 (F), CD40 (G), CD83 (H), and B7H1 (PDL1) I-Ab (I) on CD8+CD11c+ DCs or CD8−CD11c+ DCs. Tomomi Toubai et al. Blood 2011;118:192-204 ©2011 by American Society of Hematology

Reconstitution of DCs, numbers, and phenotype in the [B6 → B6Ly5 Reconstitution of DCs, numbers, and phenotype in the [B6 → B6Ly5.2] and [Ik−/− → B6 Ly5.2] chimeras. Reconstitution of DCs, numbers, and phenotype in the [B6 → B6Ly5.2] and [Ik−/− → B6 Ly5.2] chimeras. WT B6 Ly5.2 animals were lethally irradiated with 11 Gy and infused with 5 × 106 BM cells and 5 × 106 splenocytes from syngeneic Ly5.1 WT B6 or Ik−/− B6 donors. Four months later, these animals (n = 4-5 animals/group) were killed and the splenocytes were harvested and analyzed for total splenocyte count (A), frequency and number of CD11c+ DCs (B), and frequency and absolute numbers of CD8+CD11c+ DCs and CD8−CD11c+ DCs (C). The CD8+CD11c+ and CD8−CD11c+ DCs were analyzed for expression of CD80 (D), CD86 (E), CD40 (F), CD83 (G), and B7H1 (PD-L1) (I) I-Ab. *P < .05, **P < .01. Tomomi Toubai et al. Blood 2011;118:192-204 ©2011 by American Society of Hematology

LPS stimulation of DCs. BMDCs were harvested and stimulated through TLR-4 with LPS (1 μg/mL) or diluent control for 16 hours. LPS stimulation of DCs. BMDCs were harvested and stimulated through TLR-4 with LPS (1 μg/mL) or diluent control for 16 hours. Supernatants were analyzed for TNF-α (A), IL-6 (B), IL-1β (C), and IL-10 (D) with ELISA. **P < .01, ***P < .001. Tomomi Toubai et al. Blood 2011;118:192-204 ©2011 by American Society of Hematology

Ikaros-deficient DCs show enhanced stimulation of allogeneic T cells. Ikaros-deficient DCs show enhanced stimulation of allogeneic T cells. (A) BMDCs and peritoneal macrophages from WT (n = 3 mice/group), Ik−/− (n = 3 mice/group) and IkDN+/− B6 (n = 3 mice/group) animals were used as stimulators in an MLR with T cells from either BALB/c (allogeneic) or C57BL/6 (syngeneic) mice and analyzed for T-cell proliferation with 3H-thymidine incorporation at 96 hours. Data are means ± SEM of quadruplicate cultures. Results are from 1 of 3 similar experiments with the DCs and 1 of 4 for the macrophages. (B) Supernatants from the cultures were collected at 72 hours and analyzed for IFN-γ and IL-17A by ELISA. Data are means ± SEM of quadruplicate cultures. Results are from 1 of 3 similar experiments. (C) Analysis of T-cell phenotype after cultures with WT or Ik−/− DCs. CD4+ T cells were harvested after 96-hour culture with DCs and analyzed for expression of CD44, CD62L, CD25, CD69, and Foxp3 on CD4+ cells. Data are means ± SEM of quadruplicate cultures. Results are from 1 of 2 similar experiments. (D) CFSE-labeled splenic CD90+ T cells from BALB/c mice were cultured for 96 hours with B6 BMDCs from WT, Ik−/−, or IkDN+/− animals, harvested, and analyzed for CFSE and Annexin V on cells gated for CD3+. Data shown are representative of 1 of 3 similar experiments. (E) Ik−/− with WT BMDCs were mixed at the indicated ratios and used as stimulators in an MLR against BALB/c T cells. Shown is T-cell proliferation with 3H-thymidine incorporation at 96 hours. Data are means ± SEM of triplicate cultures. Results are from 1 of 2 similar experiments. (F) Treg suppression assay. BALB/c CD4+CD25− T cells were cultured with either WT or Ik−/− BMDCs along with BALB/c CD4+CD25+ Tregs at the indicated ratios. Proliferation was assessed after 5-day cultures with 3H-thymidine for the last 16 hours. Data are means ± SEM of quadruplicate cultures. Results are from 1 of 2 similar experiments. Tomomi Toubai et al. Blood 2011;118:192-204 ©2011 by American Society of Hematology

Ik−/− DCs show enhanced Notch signaling. Ik−/− DCs show enhanced Notch signaling. (A) DCs were harvested from Ik−/− or WT B6 animals (n = 3-5 mice/group) and analyzed by Q-PCR for constitutive expression of Notch receptors (Notch1-3) and their ligands (Jagged-1 and Jagged-2). (B) Notch target genes, Hes1, Deltex1, and pTa, in BMDCs and splenic DCs. Data are from 1 of 3 different experiments. (C) DCs from B6 WT, Ik−/−, and IkDN+/− animals were pretreated with DAPT for 12 hours and then used as stimulators in an MLR with T cells from syngeneic B6 or allogeneic BALB/c animals. Proliferation was determined by 3H-thymidine incorporation at 96 hours. Data are means ± SEM of quadruplicate cultures. Results are from 1 of 3 similar experiments. (D) T cells from CD4-Cre DNMAMAL animals were used as responders with BALB/c BMDCs that were pretreated with DAPT or control. Proliferation was determined by 3H-thymidine incorporation at 96 hours. Data are means ± SEM of quadruplicate cultures. Results are from 1 of 2 similar experiments. Tomomi Toubai et al. Blood 2011;118:192-204 ©2011 by American Society of Hematology

Notch signaling blockade with a γ-secretase inhibitor mitigates T-cell expansion in chimeras with Ik−/− host APCs. WT B6 Ly5.2 animals were lethally irradiated with 11 Gy and infused with 5 × 106 BM cells and 5 × 106 splenocytes from syngeneic Ly5.1 WT B6 o... Notch signaling blockade with a γ-secretase inhibitor mitigates T-cell expansion in chimeras with Ik−/− host APCs. WT B6 Ly5.2 animals were lethally irradiated with 11 Gy and infused with 5 × 106 BM cells and 5 × 106 splenocytes from syngeneic Ly5.1 WT B6 or Ik−/− B6 donors. Four months later, these chimeras [B6 → B6Ly5.2] or [Ik−/− → B6Ly5.2] chimeras were re-irradiated with 9 Gy and transplanted with 2 × 106 CD90+ T cells along with 5 × 106 BM cells from either syngeneic B6 (n = 4/group) or allogeneic MHC-matched, multiple miHA-mismatched C3H.sw donors (n = 8/group). They were also injected IP with the γ-secretase inhibitor DAPT (5 μg/kg) on days −1, +1, and +3 after BMT. (A) The animals were analyzed for GVHD with as shown by body weight loss at day 10. Shown are C3H.sw → [Ik−/− → B6Ly5.2] (○) versus C3H.sw → [Ik−/− → B6 Ly5.2] + DAPT (□) (n = 8 mice/group, P < .05) and C3H.sw → [B6 → B6Ly5.2] (●) versus C3H.sw → [B6 → B6 Ly5.2] + DAPT (■) (n = 8 mice/group, P = not significant). (B) Donor CD4+ and CD8+ T-cell expansion at day 10. Shown are C3H.sw → [Ik−/− → B6Ly5.2] (○) versus C3H.sw → [Ik−/− → B6 Ly5.2] + DAPT (□) (P < .05) and C3H.sw → [B6 → B6Ly5.2] (●) versus C3H.sw → [B6 → B6 Ly5.2] + DAPT (■) (n = 8 mice/group, P = not significant). Tomomi Toubai et al. Blood 2011;118:192-204 ©2011 by American Society of Hematology